{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Greater than grade 2 toxicity will be assessed by Common Terminology Criteria for Adverse Events.","groups":[{"description":"Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.\n\nPembrolizumab: Given 200 mg/kg IV.\n\nRadiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.","id":"OG000","title":"Radiation Therapy, Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 months after study start","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}